ArticleTheranostics2020
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab.International journal of hematology · 2026Article
- Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma.Frontiers in immunology · 2026Article
- CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.Scientific reports · 2025Article
- Application of nanobody‑based CAR‑T in tumor immunotherapy (Review).International journal of molecular medicine · 2025Review
- Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.Cell communication and signaling : CCS · 2025Review
- CD38 as theranostic target in oncology.Journal of translational medicine · 2024Review
- Single domain Camelid antibody fragments for molecular imaging and therapy of cancer.Frontiers in oncology · 2023Review
- Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.Frontiers in immunology · 2022Review
- Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.Frontiers in immunology · 2022Article
- CD38-specific nanobodies allowFrontiers in immunology · 2022Article
- A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein.Immunity, inflammation and disease · 2021Article
- Nanobodies: new avenue to treat kidney disease.Cell and tissue research · 2021Review
- Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.Theranostics · 2021Article
- Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.Frontiers in immunology · 2021Article
- Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NADCancers · 2020Article
- Review
- Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.Virus research · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 1 country.
Levin SchriewerDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Kerstin SchützeDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Katharina PetryDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Julia HambachDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
William FumeyDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Julia KoenigsdorfDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Natalie BaumDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Stephan MenzelInstitute of Immunology, University Medical Center, Hamburg-Eppendorf, Germany.
Björn RissiekDepartment of Neurology, University Medical Center, Hamburg-Eppendorf, Germany.
Kristoffer RieckenResearch Department Cell and Gene Therapy, University Medical Center, Hamburg-Eppendorf, Germany.
Boris FehseResearch Department Cell and Gene Therapy, University Medical Center, Hamburg-Eppendorf, Germany.
Jana Larissa RöckendorfDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Joanna SchmidDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Birte AlbrechtDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Hans PinnschmidtInstitute of Medical Biometry and Epidemiology, University Medical Center, Hamburg-Eppendorf, Germany.
Francis AyukDepartment of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany.
Mascha BinderDepartment of Oncology and Hematology, University Medical Center, Hamburg-Eppendorf, Germany.
Gunter SchuchHematology and Oncology Center Altona (HOPA), Hamburg, Germany.
Timon HansenHematology and Oncology Center Altona (HOPA), Hamburg, Germany.
Friedrich HaagInstitute of Immunology, University Medical Center, Hamburg-Eppendorf, Germany.
Gerhard AdamDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
Friedrich Koch-NolteInstitute of Immunology, University Medical Center, Hamburg-Eppendorf, Germany.
Peter BannasDepartment of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DEUniversity Hospital in Halle · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
ADP-ribosyl Cyclase 1AgedAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorEpitopesFemaleHematologic NeoplasmsHumansImmunoglobulin GImmunoglobulin Heavy ChainsMaleMembrane GlycoproteinsMiceMice, SCIDMiddle AgedADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedCD38 protein, humanEpitopesImmunoglobulin GImmunoglobulin Heavy ChainsMembrane GlycoproteinsSingle-Domain Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.